RHOA and neoplasm: Notably, mutations in the ORL cell lines recapitulate similar mutations in tumor tissues where mutations that were reported in the effector domain of RHOA were also detected in two ORL cell lines (ORL-156, ORL-196), suggesting that defects within this particular domain could regulate RHOA activity and provide a survival advantage to tumor growth [19].